Immunic, INC. (IMUX) — 10-Q Filings

All 10-Q filings from Immunic, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Immunic's Losses Widen Amidst R&D Spend, Liquidity Concerns Mount — Nov 13, 2025 Risk: high
Immunic, Inc. (IMUX) reported a net loss of $25.579 million for the three months ended September 30, 2025, an increase from $24.368 million in the prior-year pe
IMMUNIC's Losses Widen Amid Increased R&D Spend — Aug 7, 2025 Risk: high
IMMUNIC, INC. reported a net loss of $20.9 million for the three months ended June 30, 2025, a significant increase from the $16.7 million net loss in the same
IMMUNIC, INC. Files Q1 2025 10-Q Report — May 15, 2025 Risk: low
IMMUNIC, INC. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as VITAL THERAPIES INC, is based in New York and oper
IMMUNIC, INC. Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
IMMUNIC, INC. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as VITAL THERAPIES INC, is based in New York and operates in
IMMUNIC, INC. Files Q2 2024 10-Q Report — Aug 8, 2024 Risk: medium
IMMUNIC, INC. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key fi
IMMUNIC, INC. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
IMMUNIC, INC. (IMUX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. IMMUNIC, INC. filed a 10-Q report for the period ending March 31, 2024. The co

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX